IRBESARTAN IN THE CLINICAL PRACTICE

IRBESARTAN IN THE CLINICAL PRACTICE

Show other versions (1)

<p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers...

Full description

Bibliographic Details
Main Authors: V. I. Podzolkov, A. I. Tarzimanova
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-09-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
ирбесартан
блокаторы рецепторов к ангиотензину
артериальная гипертензия
нефропротективный эффект
Online Access:http://www.rpcardio.ru/jour/article/view/306
id doaj-76222f482f73492a97cded9e8ddcdeb8
record_format Article
spelling doaj-76222f482f73492a97cded9e8ddcdeb82020-11-24T23:59:45ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-09-0110665966410.1234/1819-6446-2014-6-659-664306IRBESARTAN IN THE CLINICAL PRACTICEV. I. Podzolkov0A. I. Tarzimanova1Первый Московский Государственный Медицинский Университет им. И.М. СеченоваПервый Московский Государственный Медицинский Университет им. И.М. Сеченова<p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented.</p>http://www.rpcardio.ru/jour/article/view/306ирбесартанблокаторы рецепторов к ангиотензинуартериальная гипертензиянефропротективный эффект
collection DOAJ
language English
format Article
sources DOAJ
author V. I. Podzolkov
A. I. Tarzimanova
spellingShingle V. I. Podzolkov
A. I. Tarzimanova
IRBESARTAN IN THE CLINICAL PRACTICE
Racionalʹnaâ Farmakoterapiâ v Kardiologii
ирбесартан
блокаторы рецепторов к ангиотензину
артериальная гипертензия
нефропротективный эффект
author_facet V. I. Podzolkov
A. I. Tarzimanova
author_sort V. I. Podzolkov
title IRBESARTAN IN THE CLINICAL PRACTICE
title_short IRBESARTAN IN THE CLINICAL PRACTICE
title_full IRBESARTAN IN THE CLINICAL PRACTICE
title_fullStr IRBESARTAN IN THE CLINICAL PRACTICE
title_full_unstemmed IRBESARTAN IN THE CLINICAL PRACTICE
title_sort irbesartan in the clinical practice
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2015-09-01
description <p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented.</p>
topic ирбесартан
блокаторы рецепторов к ангиотензину
артериальная гипертензия
нефропротективный эффект
url http://www.rpcardio.ru/jour/article/view/306
work_keys_str_mv AT vipodzolkov irbesartanintheclinicalpractice
AT aitarzimanova irbesartanintheclinicalpractice
_version_ 1725446309546033152

Similar Items